Tue. 7 Sep 2021, 9:54am ETBenzinga
In: Biotech, News, Penny Stocks, Health Care, Small Cap, General

United Therapeutics Corporation (NASDAQ:UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH).

  • Related Content: In June FDA Accepted Tyvaso DPI Application Under Priority Review.
  • United Therapeutics has developed Tyvaso DPI under a collaboration and license agreement with MannKind Corporation (NASDAQ:MNKD)
  • Data were presented at the European Respiratory Society (ERS) International Congress 2021.
  • Tyvaso DPI is a next-generation dry powder formulation of Tyvaso (treprostinil) Inhalation Solution, currently under FDA review. 
  • If approved, Tyvaso DPI is expected to provide a more convenient administration method than traditional nebulized Tyvaso therapy.
  • The transition from nebulized Tyvaso to Tyvaso DPI demonstrated safety and tolerance with significant improvements in six-minute walk distance (6MWD) and other key factors.
  • Three weeks after switching from Tyvaso to Tyvaso DPI, patients demonstrated improvements of 11.5 meters in 6MWD compared to baseline.
  • Significant improvements were observed in overall satisfaction with the Tyvaso DPI inhaler.
  • Significant improvements in PAH impacts were observed in physical impacts and cognitive/emotional impacts.
  • Price Action: UTHR shares are down 1.02% at $208.66, while MNKD stock is up 1.91% at $4.81 during the market session on the last check Tuesday.